| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 100 | 1,060 | 400 | 410 | 530 |
| Sales Growth | -90.57% | +165.00% | -2.44% | -22.64% | -1.85% |
| Net Income | -4,780 | -5,330 | -10,200 | -3,870 | -7,550 |
| Net Income Growth | +10.32% | +47.75% | -163.57% | +48.74% | +41.92% |
MGT Capital Investments Inc (MGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MGT Capital Investments, Inc. was originally incorporated as a Utah corporation in 1977 and was re-incorporated in Delaware in 2000. It is a holding Company in the global Healthcare Information Technology sector. The Company currently has a controlling interest in its two main operating subsidiaries: Medicsight PLC and Medicexchange PLC. It also has wholly owned subsidiaries MGT Capital Investments (UK) Limited, MGT Investments (Gibraltar) Limited, Medicexchange Inc., Medicsight Nominees Limited, HTTP Tech Inc. and Medical Vision Systems Inc. Medicsight and its wholly owned subsidiaries is a medical imaging software development Company listed on the AIM market of the London Stock Exchange that develops and commercializes enterprise-wide Computer-Aided Detection (CAD) applications which analyze Computer Tomography scans to assist radiologists in the early detection and measurement of colorectal polyps and lung lesions. Medicexchange and its majority owned subsidiaries provide medical imaging professionals with a global web portal containing an online sales channel for diagnostic, treatment and surgery planning solutions. This combined with a number of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing. Early detection of cancer is the key to better prognosis, less invasive and lower treatment costs, and higher survival rates. The Company's CAD software applications are intended to aid clinicians in the early detection of potential abnormalities. Medicsight has focused on two of the causes of death, colorectal cancer and lung cancer. Medicsight develops and markets ColonCAD, LungCAD and a new MedicRead visualization software application. The ColonCAD and LungCAD software are application programmable interfaces which have been seamlessly integrated into its partners' advanced 3D visualization workstations to give the clinical user a combined visualization and detection solution. 'Medicsight(r)', 'Medicsight Colon Screen(r)', 'Medicsight Lung Screen(r)', 'Medicsight Colon CAR(r)', 'Medicsight Lung CAR(r)', 'Medicsight Computer Assisted Reader(r)', 'Medicsight See More, Save More(r)' and 'Lung CAR(r)' have been registered as trademarks in the United Kingdom. 'Medicsight(r)' has also been registered in the United States, the European Union, Australia, China and a number of other countries. 'MedicRead(r)' has been registered as a trademark in the European Union. The Company's competitors could be divided into two categories: MDCT scanner manufacturers such as GE, Hitachi, Philips, Siemens and Toshiba; and independent CAD software providers.